Target intelligence / Profile preview

Undesirable gut bacteria

Molecular classification
Other
01

Overview

"Undesirable gut bacteria" refers collectively to bacterial species in the intestinal microbiome that, when overgrown or unbalanced, are associated with disease states, including inflammation, metabolic disease, neurodegenerative disorders, and infections. This is not a specific molecular target but a descriptive state of microbiome imbalance (dysbiosis), in which pathogenic or pro-inflammatory bacteria predominate over beneficial commensals, disrupting normal gut and systemic functions. Therapeutic approaches are focused on modulating the overall microbiota composition rather than targeting a discrete protein or receptor.

Other names
Harmful gut bacteriaPathogenic gut bacteria“Bad” gut bacteria
02

Mechanism of action

Suppression or elimination of undesirable species through antibiotics; Restoration of microbiome balance (e.g., by FMT or probiotics); Modulation of bacterial metabolites (e.g., inhibition of TMA production to reduce TMAO-linked atherogenesis)

03

Biological functions

Disruption of normal gut homeostasisProduction of harmful metabolitesPotential contribution to inflammationInterference with immune regulation
04

Disease associations

InflammationInfectionObesityCardiovascular diseaseNeurodegenerative diseaseMetabolic diseaseGastrointestinal disease (such as IBD)
05

Safety considerations

Use of broad-spectrum antibiotics risks further dysbiosis, antibiotic resistance, and loss of beneficial microbesFMT carries risks of infection transmissionDefining “undesirable” is context-dependent and may differ between individuals—blanket targeting has unintended consequences
06

Interacting drugs

Antibiotics (nonspecific, e.g., metronidazole, vancomycin)

4 more in the full profile.

07

Biomarkers

Microbiome diversity indices (alpha/beta diversity)Specific pathogenic bacterial counts or ratios (e.g., increased Proteobacteria, decreased Firmicutes/Bacteroidetes ratio in some dysbioses)Blood levels of trimethylamine N-oxide (TMAO)Short-chain fatty acid profilePresence of inflammatory markers

Beyond the preview

Go deeper on Undesirable gut bacteria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Undesirable gut bacteria.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call